Ethical Considerations in Selling Pharmaceuticals in Emerging Economies
Acknowledgments
This White Paper was written by Carl H. Coleman, Professor of Law, Seton Hall University School of Law, with the support of Niteesha Gupte, Assistant Professor of Law at Seton Hall through February 2017; Anthony Cocuzza, Chelsea Ott, and Erik Topp, J.D. candidates at Seton Hall; and Susy Cardoso, LL.M. candidate at Seton Hall. Professor John Jacobi provided valuable comments on a previous draft. The White Paper grew out of informal discussions with representatives of Janssen Pharmaceuticals, who approached the Center for Health & Pharmaceutical Law & Policy with a broad range of questions about ethical considerations related to corporate access to medicines strategies. Following these discussions, Janssen provided funding to the Center to convene a two-day meeting of experts and stakeholders to provide input on these questions. The meeting, which took place in October, 2016, included academics, government officials, health care providers, patient representatives, and industry representatives from nearly a dozen countries throughout Europe, Asia, Africa, and the Americas. A list of meeting participants is included in the Appendix to this White Paper. The Center is grateful to everyone who participated in the meeting for their time and expertise. However, all opinions and recommendations in this White Paper are solely those of the Center and do not necessarily reflect the views of Janssen Pharmaceuticals or the individuals who participated in the meeting. In addition, Janssen Pharmaceuticals played no role in identifying the meeting participants or any other experts and stakeholders consulted throughout this project, nor did it have any control over the content of this White Paper.
SETON HALL LAW
II ii